GW Pharmaceuticals PLC- (NASDAQ:GWPH) was downgraded by equities researchers at Stifel Nicolaus from a "buy" rating to a "hold" rating in a research note issued on Tuesday, The Fly reports.
A number of other equities analysts also recently weighed in on GWPH. Northland Securities began coverage on shares of GW Pharmaceuticals PLC- in a research note on Wednesday, April 8th. They issued an "outperform" rating and a $128.00 target price for the company. Evercore ISI lifted their price target on shares of GW Pharmaceuticals PLC- from $250.00 to $275.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 30th. Zacks Investment Research cut shares of GW Pharmaceuticals PLC- from a "buy" rating to a "hold" rating in a research report on Friday, July 3rd. Cantor Fitzgerald lifted their price target on shares of GW Pharmaceuticals PLC- from $120.00 to $154.00 and gave the stock an "overweight" rating in a research report on Thursday, May 14th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $190.00 price target on shares of GW Pharmaceuticals PLC- in a research report on Tuesday, May 12th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. GW Pharmaceuticals PLC- currently has a consensus rating of "Buy" and a consensus price target of $182.75.
Shares of NASDAQ GWPH traded up $4.29 during trading on Tuesday, reaching $132.19. The company had a trading volume of 665,800 shares, compared to its average volume of 483,369. GW Pharmaceuticals PLC- has a 52 week low of $67.98 and a 52 week high of $175.35. The stock has a market cap of $4.10 billion, a PE ratio of 134.89 and a beta of 1.94. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.64 and a current ratio of 6.50. The business's 50 day moving average price is $126.08 and its 200-day moving average price is $110.77.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its earnings results on Monday, May 11th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.88) by $0.64. GW Pharmaceuticals PLC- had a net margin of 8.42% and a negative return on equity of 9.87%. The company had revenue of $120.60 million during the quarter, compared to the consensus estimate of $84.93 million. During the same period in the previous year, the firm posted ($0.14) earnings per share. The company's revenue was up 207.7% on a year-over-year basis. Equities analysts anticipate that GW Pharmaceuticals PLC- will post -2.16 earnings per share for the current year.
In other news, Chairman Geoffrey W. Dr Guy sold 720,000 shares of the company's stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $10.25, for a total value of $7,380,000.00. Following the completion of the transaction, the chairman now owns 6,101,521 shares in the company, valued at $62,540,590.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Douglas B. Snyder sold 9,804 shares of the company's stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $10.50, for a total transaction of $102,942.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 752,100 shares of company stock valued at $7,732,092. Corporate insiders own 3.10% of the company's stock.
Several institutional investors have recently added to or reduced their stakes in GWPH. CENTRAL TRUST Co lifted its position in shares of GW Pharmaceuticals PLC- by 321.4% in the first quarter. CENTRAL TRUST Co now owns 295 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 225 shares in the last quarter. Eudaimonia Partners LLC bought a new stake in shares of GW Pharmaceuticals PLC- in the first quarter worth $26,000. Signaturefd LLC lifted its position in shares of GW Pharmaceuticals PLC- by 121.3% in the first quarter. Signaturefd LLC now owns 509 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 279 shares in the last quarter. Ameritas Investment Company LLC bought a new stake in shares of GW Pharmaceuticals PLC- in the first quarter worth $49,000. Finally, Modus Advisors LLC bought a new stake in shares of GW Pharmaceuticals PLC- in the second quarter worth $61,000. Institutional investors own 81.34% of the company's stock.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
Featured Article: Nikkei 225 Index
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Restaurant Stocks That Still Look Tasty As the Economy Reopens
As part of our national response to the Covid-19 pandemic, many Americans considered it their patriotic, if not moral, duty to support the restaurant industry. And while many consumers were intensely focused on their small, local restaurants, the national chains were still open for business during this time.
And the reality is that the national chains are going to be the most adaptable to whatever pace of economic recovery we see. Hopes for a “V” shaped recovery have pretty much gone out the window. The new model suggests a stair-step recovery may be the best-case scenario.
The worst case scenario for the restaurant industry will be one where different regions of the country are subject to rolling lockdowns. In a business with notoriously low margins, an open/close, open/close recovery would be disastrous.
It’s one reason why I’m not sure I would be diving into restaurant stocks right now. But the same was being said of airline stocks and cruise line stocks. And sure enough, discount investors have been trying to invest in these stocks.
But as all 50 states have now re-opened in some fashion, it’s not unlikely that restaurant stocks are drawing attention from investors. We’ve put together this presentation that highlights seven restaurant stocks that you should consider looking at if you want to dive into this sector.
View the "Restaurant Stocks That Still Look Tasty As the Economy Reopens".